Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
0.990
+0.040 (4.21%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Actinium Pharmaceuticals stock have an average target of 6.00, with a low estimate of 4.00 and a high estimate of 9.00. The average target predicts an increase of 506.06% from the current stock price of 0.99.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Actinium Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $4 | Buy | Reiterates | $4 | +304.04% | Jun 3, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $5 | Buy | Maintains | $5 | +405.05% | Apr 8, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $9 | Buy | Reiterates | $9 | +809.09% | Apr 3, 2026 |
Financial Forecast
Revenue This Year
n/a
from 90.00K
Decreased by -100.00%
Revenue Next Year
12.93M
EPS This Year
-0.91
from -1.09
EPS Next Year
-0.35
from -0.91
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 38.8M | |
| Avg | n/a | 12.9M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -100.0% | - | |
| Avg | -100.0% | - | |
| Low | -100.0% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.91 | -0.03 | |
| Avg | -0.91 | -0.35 | |
| Low | -0.91 | -0.67 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.